Find and Pitch Jounalists, Get Your Story Covered

Tags: Software & Services Software Platforms IT Automation Apple cell biology, Craniofacial, developmental biology, DNA repair, genetics, oxidative stress

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 days ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more - 2 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more - 5 months ago STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 6 months ago STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies - 7 months ago STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more - 7 months ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - 7 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 7 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 9 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 9 months ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - 10 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 10 months ago STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices - 10 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages - 11 months ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - 11 months ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - about 1 year ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 8 days ago Pharma execs react to final drug price negotiations with Medicare - about 1 month ago 3 Big Pharma cancer drugs facing inflation penalties - about 2 months ago The IRA will lower U.S. drug spending, CMS finds — but not for awhile - 3 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 3 months ago FDA’s platform designation aims to ease R&D pain points - 3 months ago Cutting pills. Rationing insulin. How Americans struggle to pay for drugs. - 5 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 6 months ago Could pharma’s legal attack on the IRA succeed in killing price negotiations? - 7 months ago Pharma CFOs need R&D vigilance in tough economic times - 7 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Is anyone taking the world’s priciest drugs? - 20 days ago Neuro drugs are still faltering, despite rising investment - about 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago 3 big recent trial flops - 5 months ago The biggest questions hanging over pharma in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago
4	Joyce Frieden MedPage Today Washington editor at MedPage Today. Board member at AHCJ. Greater Washington, DC area Healthcare journalism	Is Medicare's Negotiated Drug Price List Worth Celebrating? Depends on Whom You Ask. - about 1 month ago
5	Jonathan Gardner Healthcare Dive Senior reporter. BioPharma Dive. Charlottesville, Virginia BiopharmaceuticalsJournalism	Medicare drug price cuts could have limited early impact, but grow with time - about 1 month ago Biden administration goes after drug patents in bid to lower prices - 10 months ago Pharma benefited from basing business overseas. An international tax effort could spur a rethink. - 10 months ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - about 1 month ago The biotech news you missed this week - 2 months ago ICER casts doubt on Sarepta’s DMD gene therapy - 5 months ago
7	Sophie Putka MedPage Today Enterprise, investigative writer. New York, USA enterprise journalisminvestigative journalism	Can Individual States Effectively Cap Prescription Drug Costs? - 3 months ago
8	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma’s fight against drug price reforms takes weird, desperate turn - 3 months ago Big Pharma spends billions more on executives and stockholders than on R&D - 7 months ago Big Pharma fought drug pricing reform with record $7.5M dark money donation - 10 months ago
9	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 3 months ago
10	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Gas prices are hurting biotech - 5 months ago Eli Lilly tries a rare tactic: competing on price - 11 months ago

Journalists covering drug development | Drug prices | drug pricing | Pharmaceuticals | pharmalittle | research